Marvin MD - Entia Biosciences Chairman Officer
| ERGO Stock | USD 0.0002 0.00 0.00% |
Insider
Marvin MD is Chairman Officer of Entia Biosciences
| Age | 82 |
| Phone | 971-228-0709 |
| Web | https://www.entiabio.com |
Entia Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.6437) % which means that it has lost $1.6437 on every $100 spent on assets. This is way below average. Entia Biosciences' management efficiency ratios could be used to measure how well Entia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Klaus Orlinger | Hookipa Pharma | 47 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Eyal MBA | Protalix Biotherapeutics | 49 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Balu Balasubramanian | OUTLOOK THERAPEUTICS INC | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Joel Prieve | OUTLOOK THERAPEUTICS INC | N/A | |
| Lisa Peraza | Heron Therapeuti | 47 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Rick Gregory | OUTLOOK THERAPEUTICS INC | N/A | |
| Jeffrey Evanson | OUTLOOK THERAPEUTICS INC | 56 | |
| Chris Storgard | Heron Therapeuti | 58 | |
| Barry PharmD | Heron Therapeuti | 67 | |
| Prof MD | Hookipa Pharma | 81 | |
Management Performance
| Return On Asset | -1.64 |
Entia Biosciences Leadership Team
Elected by the shareholders, the Entia Biosciences' board of directors comprises two types of representatives: Entia Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entia. The board's role is to monitor Entia Biosciences' management team and ensure that shareholders' interests are well served. Entia Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entia Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Timmins, CFO, COO, Executive Vice President | ||
| Marvin MD, Chairman Officer | ||
| Elliot Shelton, Secretary, Director | ||
| William Meyer, Head Production |
Entia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Entia Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.64 | |||
| Operating Margin | (4.40) % | |||
| Current Valuation | 235.63 K | |||
| Shares Outstanding | 33.66 M | |||
| Price To Earning | (0.50) X | |||
| Price To Sales | 0.89 X | |||
| Revenue | 265.47 K | |||
| Gross Profit | 173.97 K | |||
| EBITDA | (1.29 M) | |||
| Net Income | (1.4 M) |
Pair Trading with Entia Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entia Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entia Biosciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Entia Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entia Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entia Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entia Biosciences to buy it.
The correlation of Entia Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entia Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entia Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entia Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.